Characterization of the neurochemical effects of N-[2-(1- azabicyclo[3,3,0]octan-5-yl)ethyl]2-nitroaniline fumarate (SK-946) as a cognition activator

Biological and Pharmaceutical Bulletin

Volumn 21, Issue 7, 1998, Pages 704-709

  Suzuki, Tsunemasa ^a   Hirooka, Kiyotaka ^a   Kanda, Kazumi ^a   Uesaka, Hiroshi ^a   Hirooka, Hiroko ^a   Furusawa, Kenichi ^a  

^a SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

Author keywords

Central nervous; Cognition activator; Muscarinic receptor; SK 946

Indexed keywords

ANILINE DERIVATIVE; CALCIUM ION; FUMARIC ACID DERIVATIVE; METHYLSCOPOLAMINE; N [2 (1 AZABICYCLO[3,3,0]OCTAN 5 YL)ETHYL] 2 NITROANILINE FUMARATE; N [2 (1 AZABICYCLO[3.3.0]OCTAN 5 YL)ETHYL] 2 NITROANILINE FUMARATE; OXOTREMORINE M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CALCIUM CELL LEVEL; COGNITION; CONTROLLED STUDY; HIPPOCAMPUS; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; RAT; RECEPTOR AFFINITY;

EID: 0031878139     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.21.704     Document Type: Article

References (28)

1. Greenamyre J. T., Young A. B., Neurobiol. Aging, 10, 593-602 (1985).
2. Ferrier I. N., Leake A., Psychoneuroendocrinology, 15, 89-95 (1990).
3. Davies P., Maloney A. J., Lancet, II, 1403 (1976).
4. Whitehouse P. J., Price D. L., Struble R. G., Clark A. W., Coyle J. T., Delong M. R., Science, 215, 1237-1239 (1982).
5. Coyle J. T., Price D. L., Delong M. R., Science, 219, 1184-1190 (1983).
6. Jaen J. C., Moos W. H., Johnson G., Bioorg. Med. Chem. Lett., 2, 777 (1992).
7. Flynn D. D., Weinstein D. A., Mash D. C., Ann. Neurol., 29, 256-262 (1991).
8. Cutler R., Joseph J. A., Yamagami K., Villalobos-Molina R., Roth G. S., Brain Res., 664, 54-60 (1994).
9. Ferrari-DiLeo G., Mash D. C., Flynn D. D., Mol. Chem. Neuropathol., 24, 69-91 (1995).
10. Flynn D. D., Ferrari-DiLeo G., Mash D. C., Levey A. I., J Neurochem., 64, 1888-1891 (1995).
11. Mash D. C., Flynn D. D., Mol. Chem. Neuropathol., 24, 69 (1955).
12. Suzuki T., Hirooka K., Kanda K., Uesaka H., Hirooka H., Furusawa K., submitted to Biol. Pharm. Bull., (1998).
13. Alonso R., Soubrie P., Synapse, 8, 30-37 (1991).
14. Hammer R., Giraldo E., Schiavi G. B., Monferini E., Landinsky H., Life Sci., 39, 1653-1662 (1986).
15. Freedman S. B., Harley E. A., Iversen L. L., Br J. Pharmacol, 93, 437-445 (1988).
16. Whitehouse P. J., Martine A. M., Antuono P. G., Lowenstein P. R., Coyle J. T., Price D. L., Kellar K. J., Brain Res., 371, 146-151 (1986).
17. Dorje R., Wess J., Lanbrecht G., Tacke R., Mutschler E., Brann M. R., J. Pharmacol. Exp. Ther., 256, 727-733 (1991).
18. Ellman G. L., Courtney K. D., Andres V., Featherstone R. M., Biochem. Pharmacol., 7, 88 (1961).
19. Morinan A., Garratt H. M., J. Pharmacol. Methods, 13, 213-223 (1985).
20. Banker G. A., Cowan W. M., Brain Res., 126, 397-342 (1977).
21. Lenox R. H., Hendley D., Ellis J., J. Neurochem., 50, 558-564 (1988).
22. Mash D. C., Flynn D. D., Potter L. T., Science, 228, 1115-1117 (1985).
23. Araujo D. M., Lapchak P. A., Robitaille Y., Gauthier S., Quirion R., J. Neurochem., 50, 1914-1923 (1988).
24. McKinney M., Prog. Brain Res., 98, 333-340 (1993).
25. Kudo Y., Nakamura Y., Sugaya K., Noguchi K., Iijima T., Ogura A., Prog. Brain Res., 98, 323-331 (1993).
26. Batty I. H., Downes C. P., J. Neurochem., 65, 2279-2289 (1995)
27. Pearce B. D., Potter L. T., Alzheimer Dis. Assoc. Disord., 5, 163-172 (1991).
28. Wallace M. A., Claro E., Neurochem. Res., 18, 139-145 (1993).